41 results match your criteria: "BioRaN team; CNRS UMR5292; Inserm U1028; Université Lyon 1[Affiliation]"

Functional discrimination of CSF from Alzheimer's patients in a brain on chip platform.

Sci Rep

August 2025

Biochemistry and Molecular Biology Department, Neurodegenerative Pathologies, LBMMS, 59 Boulevard Pinel, Bron, Hospices Civils de Lyon, 69500, Lyon, France.

Neurodegenerative diseases, including Alzheimer's disease (AD), present significant diagnostic challenges due to overlapping symptoms and the invasive, time-consuming, and costly nature of current diagnostic methods. While AD remains the only neurodegenerative disorder for which biomarkers in cerebrospinal fluid (CSF), such as amyloid beta peptide (Aβ), are available for clinical diagnosis, similar tools are lacking for other neurodegenerative conditions. This diagnostic gap hinders timely and accurate differential diagnoses, limiting patient access to appropriate clinical trials and therapeutic interventions.

View Article and Find Full Text PDF

Human PrP E219K: a new and promising substrate for robust RT-QuIC amplification of human prions with potential for strain discrimination.

Microbiol Spectr

August 2025

Université Paris-Saclay, Institut National de Recherche pour l'Agriculture, l'Alimentation et l'Environnement, Université Versailles-Saint Quentin, Unité de Virologie et d'Immunologie Moléculaires, Jouy-en-Josas, France.

Unlabelled: Mammalian prion diseases are fatal neurodegenerative disorders caused by the conformational conversion of the host-encoded prion protein (PrP) into a pathogenic, misfolded isoform, known as PrP. Definitive diagnosis currently relies on post-mortem histopathological examination of the central nervous system. Among emerging diagnostic tools, amplification techniques such as Real-Time Quaking-Induced Conversion (RT-QuIC) have demonstrated high sensitivity, specificity, and speed, although certain prion strains remain difficult to amplify.

View Article and Find Full Text PDF

Introduction: Neurofilament light chain (NfL) quantification aids in diagnosing and predicting neurological disorders, but clinical and laboratory practices vary across centers. Differences in result interpretation and reporting further challenge test commutability. This study aimed to review the global analytical and post-analytical methods used for NfL measurement in routine clinical practice across different contexts.

View Article and Find Full Text PDF

Soluble SorLA in CSF, a novel biomarker to explore disrupted trafficking of SorLA protein in Alzheimer disease.

Alzheimers Res Ther

May 2025

Univ Rouen Normandie, Inserm U1245 and CHU Rouen, Department of Genetics and CNRMAJ, Rouen, F-76000, France.

Background: The SorLA protein, encoded by the Sortilin-related receptor 1 (SORL1) gene, is a major player in Alzheimer's disease (AD) pathophysiology. Functional studies demonstrated that SorLA deficiency results in increased production of Aβ peptide, and thus a higher risk of AD. SorLA can be subject to proteolytic shedding at the cell surface, leading to the release of the soluble ectodomain of the protein (sSorLA) in the extracellular space.

View Article and Find Full Text PDF

Toward alpha-synuclein seed amplification assay in clinical practice.

Alzheimers Dement (Amst)

January 2025

Biochemistry and Molecular Biology Department Neurodegenerative Pathologies LBMMS Hospices Civils de Lyon Lyon France.

Introduction: Seed amplification assays (SAAs) demonstrate remarkable diagnostic performance in alpha-synucleinopathies. However, existing protocols lack accessibility in routine laboratories, mainly due to the requirement for in-house production of recombinant alpha-synuclein (aSyn). This study proposes a cerebrospinal fluid (CSF) aSyn-SAA protocol using solely commercial reagents to facilitate its clinical implementation.

View Article and Find Full Text PDF

Introduction: The MAPT gene encodes Tau, a protein mainly expressed by neurons. Tau protein plays an important role in cerebral microtubule polymerization and stabilization, in axonal transport and synaptic plasticity. Heterozygous pathogenic variation in MAPT are involved in a spectrum of autosomal dominant neurodegenerative diseases known as taupathies, including Alzheimer's disease, Pick's disease, fronto-temporal dementia, cortico-basal degeneration and progressive supranuclear palsy.

View Article and Find Full Text PDF

Delayed cerebral ischemia (DCI) is a devastating complication of aneurysmal subarachnoid hemorrhage (ASAH) causing brain infarction and disability. Cerebral microdialysis (CMD) monitoring is a focal technique that may detect DCI-related neurochemical changes as an advance warning. We conducted retrospective analyses from 44 poor-grade ASAH patients and analyzed glucose, lactate, pyruvate, and glutamate concentrations in control patients without DCI (n = 19), and in patients with DCI whose CMD probe was located within (n = 17) or outside (n = 8) a new infarct.

View Article and Find Full Text PDF

Cerebrospinal fluid biomarkers in SARS-CoV-2 patients with acute neurological syndromes.

Rev Neurol (Paris)

March 2023

Service de neurologie, centre hospitalier universitaire de la Guadeloupe, Pointe-à-Pitre/Abymes, French West Indies, France; Faculté de médecine de l'université des Antilles, French West Indies, Pointe-à-Pitre, France; U 1127, CNRS, unité mixte de recherche (UMR) 7225, faculté de médecine de

Background And Purpose: Mechanisms underlying acute brain injury in SARS-CoV-2 patients remain poorly understood. A better characterization of such mechanisms remains essential to preventing long-term neurological sequelae. Our present aim was to study a panel of biomarkers of neuroinflammation and neurodegeneration in the cerebrospinal fluid (CSF) of NeuroCOVID patients.

View Article and Find Full Text PDF
Article Synopsis
  • The European task force is working on a diagnostic workflow for neurocognitive disorders in older adults, focusing on how to effectively use biomarkers despite incomplete evidence for their validity.
  • They employed a Delphi consensus method, involving 22 delegates from 11 scientific societies, to gather expert opinions and establish foundational assumptions for the workflow.
  • Preliminary results suggest a structured approach emphasizing specialized clinical settings, early-stage diagnosis (MCI-mild dementia), and specific pre-assessment screenings, setting the stage for a future comprehensive guideline that adapts with new findings.
View Article and Find Full Text PDF

The human brain is a complex organ composed of many different types of cells interconnected to create an organized system able to efficiently process information. Dysregulation of this delicately balanced system can lead to the development of neurological disorders, such as neurodegenerative diseases (NDD). To investigate the functionality of human brain physiology and pathophysiology, the scientific community has been generated various research models, from genetically modified animals to two- and three-dimensional cell culture for several decades.

View Article and Find Full Text PDF

Proteinopathies associated to repeat expansion disorders.

J Neural Transm (Vienna)

February 2022

Laboratory of Neurobiology and Neurogenetics, Department of Biochemistry and Molecular Biology, Lyon University Hospital, Bron, France.

The most common neurodegenerative disorders, such as Alzheimer's or Parkinson's diseases, are characterized by synaptic dysfunction, neuronal loss and proteinaceous aggregates in central nervous system. The deposition of misfolded proteins constitutes neuropathological hallmarks of these diseases, grouped in the generic term of proteinopathies. Apart from these, other neurodegenerative diseases are characterized by genetic abnormalities like unstable repetitive simple sequence tracts (microsatellites) dispersed throughout the human genome.

View Article and Find Full Text PDF
Article Synopsis
  • - The practice of measuring cerebrospinal fluid (CSF) biomarkers for diagnosing Alzheimer's disease (AD) is inconsistent across different medical centers, leading to varied interpretations of the same results.
  • - A study involving 40 centers worldwide analyzed their analytical protocols and reports to create a consensus on how to interpret CSF biomarker profiles effectively.
  • - The findings highlighted that while the analytical methods were largely similar, there was significant variability in how results were reported; as a result, harmonized reporting formats were established for clearer communication among laboratories.
View Article and Find Full Text PDF

Prion strains associated with iatrogenic CJD in French and UK human growth hormone recipients.

Acta Neuropathol Commun

August 2021

UMR INRAE ENVT 1225, Interactions Hôtes-Agents Pathogènes, École Nationale Vétérinaire de Toulouse, 23 Chemin des Capelles, 31076, Toulouse, France.

Treatment with human pituitary-derived growth hormone (hGH) was responsible for a significant proportion of iatrogenic Creutzfeldt-Jakob disease (iCJD) cases. France and the UK experienced the largest case numbers of hGH-iCJD, with 122 and 81 cases respectively. Differences in the frequency of the three PRNP codon 129 polymorphisms (MM, MV and VV) and the estimated incubation periods associated with each of these genotypes in the French and the UK hGH-iCJD cohorts led to the suggestion that the prion strains responsible for these two hGH-iCJD cohorts were different.

View Article and Find Full Text PDF

Objective: The 'Frontotemporal dementia-Amyotrophic lateral sclerosis Spectrum' (FAS) encompasses different phenotypes, including cognitive disorders (frontotemporal dementia, FTD) and/or motor impairments (amyotrophic lateral sclerosis, ALS). The aim of this study was to apprehend the specific uses of neurofilaments light chain (NfL) and phosphorylated neurofilaments heavy chain (pNfH) in a context of FAS.

Methods: First, NfL and pNfH were measured in 39 paired cerebrospinal fluid (CSF) and plasma samples of FAS and primary psychiatric disorders (PPD) patients, considered as controls.

View Article and Find Full Text PDF

Core cerebrospinal fluid biomarker profile in anti-LGI1 encephalitis.

J Neurol

January 2022

Service de Neurocognition Et Neuro-Ophtalmologie, Hôpital Neurologique Pierre Wertheimer, Bron Cedex, France.

Objective: To compare CSF biomarkers' levels in patients suffering from anti-Leucine-rich Glioma-Inactivated 1 (LGI1) encephalitis to neurodegenerative [Alzheimer's disease (AD), Creutzfeldt-Jakob's disease (CJD)] and primary psychiatric (PSY) disorders.

Methods: Patients with LGI1 encephalitis were retrospectively selected from the French Reference Centre database between 2010 and 2019 and enrolled if CSF was available for biomarkers analysis including total tau (T-tau), phosphorylated tau (P-tau), amyloid-beta Aβ1-42, and neurofilaments light chains (Nf L). Samples sent for biomarker determination as part of routine practice, and formally diagnosed as AD, CJD, and PSY, were used as comparators.

View Article and Find Full Text PDF

DAMPs and RAGE Pathophysiology at the Acute Phase of Brain Injury: An Overview.

Int J Mol Sci

February 2021

Department of Neurological Anesthesiology and Intensive Care Medicine, Hospices Civils de Lyon, Hôpital Edouard Herriot, 69003 Lyon, France.

Early or primary injury due to brain aggression, such as mechanical trauma, hemorrhage or is-chemia, triggers the release of damage-associated molecular patterns (DAMPs) in the extracellular space. Some DAMPs, such as S100B, participate in the regulation of cell growth and survival but may also trigger cellular damage as their concentration increases in the extracellular space. When DAMPs bind to pattern-recognition receptors, such as the receptor of advanced glycation end-products (RAGE), they lead to non-infectious inflammation that will contribute to necrotic cell clearance but may also worsen brain injury.

View Article and Find Full Text PDF

Background: Several studies have investigated the value of alpha-synuclein assay in the cerebrospinal fluid (CSF) of Alzheimer's disease (AD) and dementia with Lewy bodies (DLB) patients in the differential diagnosis of these two pathologies. However, very few studies have focused on this assay in AD and DLB patients at the MCI stage.

Methods: All patients were enrolled under a hospital clinical research protocol from the tertiary Memory Clinic (CM2R) of Alsace, France, by an experienced team of clinicians.

View Article and Find Full Text PDF

An automated alert system based on the p-Tau/Tau ratio to quickly inform health professionals upon a suspected case of sporadic Creutzfeldt-Jakob disease.

J Neurol Sci

August 2020

CHU Tours, Service de de médecine nucléaire in vitro, F-37044 Tours, France; UMR 1253, iBrain, Université de Tours, Inserm, Tours, France; Groupe de Biologie Spécialisée de la Société Française de Médecine Nucléaire, France.

Introduction: Knowing the risk of potential sporadic Creutzfeldt-Jakob disease (sCJD) instrument-contamination is essential in hospitals. We examined the relevance of the p-Tau/Tau ratio to exclude a probable case of sCJD in clinical practice, and we established an alert system to quickly inform health professionals in case of positivity.

Methods: This retrospective study was conducted on 143 cerebrospinal fluid samples from patients suspected for sCJD.

View Article and Find Full Text PDF

Significance and Diagnostic Accuracy of Early S100B Serum Concentration after Aneurysmal Subarachnoid Hemorrhage.

J Clin Med

June 2020

Hospices Civils de Lyon, Hôpital Pierre Wertheimer, Department of Neurological Anesthesiology and Intensive Care Medicine, 69500 Lyon, France.

Background: Early brain injuries (EBI) are one of the most important causes of morbidity and mortality after subarachnoid hemorrhage. At admission, a third of patients are unconscious (spontaneously or sedated) and EBI consequences are not evaluable. To date, it is unclear who will still be comatose (with severe EBI) and who will recover (with less severe EBI) once the aneurysm is treated and sedation withdrawn.

View Article and Find Full Text PDF

Background And Purpose: Neuropsychiatric symptoms are commonly observed in neurodegenerative diseases. No biomarker is currently available to diagnose psychiatric conditions. As a consequence, the distinction between psychiatric and neurodegenerative disorders can be challenging in daily practice.

View Article and Find Full Text PDF

Predictive testing for Huntington disease over 24 years: Evolution of the profile of the participants and analysis of symptoms.

Mol Genet Genomic Med

October 2019

Service de neurogénétique et médecine prédictive, GH Nord-Hôpital de la Croix Rousse, Hospices civils de Lyon, Lyon, France.

Background: Huntington disease (HD) is a devastating neurodegenerative autosomal dominant genetic condition. Predictive testing (PT) is available through a defined protocol for at-risk individuals. We analyzed the over-24-years evolution of practices regarding PT for HD in a single center.

View Article and Find Full Text PDF

Choroid plexus (ChPs) are involved in the early inflammatory response that occurs in many brain disorders. However, the activation of immune cells within the ChPs in response to neuroinflammation is still largely unexplored in-vivo. There is therefore a crucial need for developing imaging tool that would allow the non-invasive monitoring of ChP involvement in these diseases.

View Article and Find Full Text PDF

The standardization of cerebrospinal fluid markers and neuropathological diagnoses brings to light the frequent complexity of concomitant pathology in Alzheimer's disease: The next challenge for biochemical markers?

Clin Biochem

October 2019

Institut de Pathologie Est -Neuropathologie, Hospices civils de Lyon, Lyon, France; University Claude Bernard Lyon 1, Lyon, France; Department of Cancer Cell Plasticity, Cancer Research Centre of Lyon, INSERM U1052, CNRS UMR5286, Lyon, France. Electronic address:

During the last two decades, neuropathological examination of the brain has evolved both technically and scientifically. The increasing use of immunohistochemistry to detect protein aggregates paralleled a better understanding of neuroanatomical progression of protein deposition. As a consequence, an international effort was achieved to standardize hyperphosphorylated-Tau (phospho-TAU), ßAmyloid (Aß), alpha syncuclein (alpha-syn), phosphorylated transactive response DNA-binding protein 43 (phospho-TDP43) and vascular pathology detection.

View Article and Find Full Text PDF